Open AccessGuillain-Barre Syndrome Following Ad26.Cov2.S Covid-19 Vaccine: A Case Report
Author(s) -
Sushmita Khanal,
Sunil Babu Khanal
Publication year - 2021
Publication title -
journal of nobel medical college
Language(s) - English
Resource type - Journals
eISSN - 2091-234X
pISSN - 2091-2331
DOI - 10.3126/jonmc.v10i2.41790
Subject(s) - medicine , guillain barre syndrome , covid-19 , dermatology , pediatrics , virology , disease , outbreak , infectious disease (medical specialty)
Guillain-Barre Syndrome has been reported as a rare side effect in the recipients of Johnson & Johnson®'s Janssen Ad26.COV2.S COVID-19 vaccine. We report a case of Guillain-Barre Syndrome in a 50 years old female following the administration of the aforementioned vaccine.